Prokarium's CEO explains how the company is harnessing bacteria as a therapy, and in the future as a deliverer of therapies

blonca9
Apr 29, 2024
1 min read

Kristen Albright describes Prokarium's bladder cancer program, which went into the clinic earlier this year, and a platform (including a partnership with Ginkgo) that is designed to use bacteria to deliver therapeutic payloads.

Recent Posts

See All

RBC Global Healthcare Conference: Korro Bio entered the clinic with its RNA editing platform in January and will have multiple cohorts of data in AATD later this year

RBC Global Healthcare Conference: With a phase 3 for its lead program scheduled to read in Q3 and mid-stage data for another program coming up this quarter, aTyr Pharma has pivotal months ahead

RBC Global Healthcare Conference: Ocular Therapeutix's Chairman & CEO Pravin Dugel provides an update on the progress of the pivotal studies for AXPAXLI in wet AMD

Prokarium's CEO explains how the company is harnessing bacteria as a therapy, and in the future as a deliverer of therapies

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight